MML Investors Services LLC Acquires Shares of 10,674 Hims & Hers Health, Inc. (NYSE:HIMS)

MML Investors Services LLC purchased a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 10,674 shares of the company’s stock, valued at approximately $197,000.

A number of other institutional investors and hedge funds have also modified their holdings of HIMS. Bank of New York Mellon Corp lifted its position in Hims & Hers Health by 67.5% during the second quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock worth $13,701,000 after buying an additional 273,473 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Hims & Hers Health by 322.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 52,312 shares of the company’s stock worth $1,056,000 after purchasing an additional 39,943 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Hims & Hers Health by 33.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 27,830 shares of the company’s stock valued at $562,000 after buying an additional 6,912 shares in the last quarter. Panagora Asset Management Inc. grew its position in Hims & Hers Health by 246.2% in the 2nd quarter. Panagora Asset Management Inc. now owns 378,192 shares of the company’s stock valued at $7,636,000 after acquiring an additional 268,949 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Hims & Hers Health by 763.4% during the 2nd quarter. Principal Financial Group Inc. now owns 143,793 shares of the company’s stock worth $2,903,000 after buying an additional 127,138 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 7,500 shares of Hims & Hers Health stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $26.00, for a total value of $195,000.00. Following the transaction, the insider now owns 193,601 shares of the company’s stock, valued at approximately $5,033,626. This trade represents a 3.73 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Oluyemi Okupe sold 18,959 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $25.77, for a total transaction of $488,573.43. Following the sale, the chief financial officer now directly owns 132,578 shares in the company, valued at approximately $3,416,535.06. This trade represents a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,111,616 shares of company stock worth $27,448,767. 17.71% of the stock is owned by insiders.

Analysts Set New Price Targets

HIMS has been the subject of several recent research reports. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research note on Tuesday, November 5th. Morgan Stanley started coverage on shares of Hims & Hers Health in a research note on Tuesday, December 17th. They set an “overweight” rating and a $42.00 price target on the stock. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. Finally, TD Cowen reissued a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of “Hold” and an average target price of $22.80.

Hims & Hers Health Stock Performance

HIMS opened at $28.49 on Friday. The company has a market capitalization of $6.22 billion, a P/E ratio of 64.75 and a beta of 1.25. The company has a 50-day moving average of $26.29 and a 200-day moving average of $21.46. Hims & Hers Health, Inc. has a 1-year low of $8.09 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same period in the previous year, the company earned ($0.04) earnings per share. Hims & Hers Health’s quarterly revenue was up 77.1% on a year-over-year basis. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.